摘要
以免疫检查点抑制剂(ICIs)为代表的免疫治疗掀起肿瘤治疗的革命,多种ICIs治疗肝细胞癌的早期临床研究数据显示其良好的应用前景,迎来了肝细胞癌的免疫治疗时代。近来一项ICIs联合抗血管生成治疗的Ⅲ期临床研究结果显示其疗效和安全性优于标准治疗,有望成为肝细胞癌新的一线标准治疗。目前ICIs联合放化疗、抗血管生成治疗及局部治疗的研究正在全世界开展,将进一步刷新肝细胞癌系统治疗的格局。
Immunotherapy,especially immune checkpoint inhibitors(ICIs),has reformed the situation of cancer management.Encouraging results have been revealed in early stage studies about ICIs in patients with hepatocellular carcinoma.Results of a recent phaseⅢstudy of ICIs combined with anti-angiogenesis therapy in the treatment of hepatocellular carcinoma have achieved a positive result,showing superior advantages in efficacy and safety compared with standard manage-ment.At present,lots of studies in hepatocellular carcinoma patients treated with ICIs combining with traditional therapy like chemotherapy,radiotherapy,antiangiogenetic therapy,locore-gional therapy and another ICIs are held globally.These results will update the strategies of hepatocellular carcinoma.
作者
李相成
陈晓锋
郑侠
Li Xiangcheng;Chen Xiaofeng;Zheng Xia(Hepatobiliary Center,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China;Department of Oncology,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China;Department of Oncology,81 Hospital Affiliated to Nanjing University of Chinese Medicine,Nanjing 210002,China)
出处
《中华消化外科杂志》
CAS
CSCD
北大核心
2020年第2期123-129,共7页
Chinese Journal of Digestive Surgery
基金
国家自然科学基金重点项目(31930020)
国家自然科学基金(81530048、81470901、81670570)
江苏省重点病种规范化诊疗研究(BE2016789)。
关键词
肝肿瘤
免疫治疗
免疫检查点抑制剂
联合治疗
进展
Hepatic neoplasms
Immuotherapy
Immune check point inhibitors
Combined therapy
Progress
